CureVac N.V. (FRA:5CV)

Market Cap	1.07B
Revenue (ttm)	70.74M
Net Income (ttm)	128.82M
Shares Out	n/a
EPS (ttm)	0.80
PE Ratio	8.28
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,503
Average Volume	17,138
Open	4.380
Previous Close	4.464
Day's Range	4.336 - 4.380
52-Week Range	2.150 - 4.948
Beta	n/a
RSI	37.51
Earnings Date	Nov 12, 2025

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In ad...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 983
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5CV